(A) Localization of RPA1 and RPB1 in DMS53-CR cells treated with vehicle or MPA, with or without guanosine or cycloheximide for 8 hours. Nuclei are stained with DAPI (blue). Original magnification, 63×. (B) Nuclear RPA1 immunofluorescence signals for cells in A. 50–100 cells were quantified in each group. **P < 0.01, ****P < 0.0001. (C–F) qPCR for the rDNA promoter and 18S, 5.8S, and 28S coding regions after ChIP with an anti-RPA1 antibody or IgG control. DMS53-CR cells were treated with MPA or vehicle, with or without guanosine for 12 hours. DMS53, the treatment-naive parental cell line of DMS53-CR, is included as a reference. Two independent primer pairs (P1, P2) were designed for each region. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are shown as mean and SD (B–F). Statistical significance was assessed using 1-way ANOVA with Tukey’s multiple-comparison test (B–F). All experiments were repeated twice or more.